Growth-Oriented Top Gainer NASDAQ and NYSE Stocks (CYCC, YONG, ISIS, EDU)

Los Angelas, CA -- (SBWIRE) -- 10/15/2012 -- Cyclacel Pharmaceuticals (NASDAQ: CYCC) shares rose 34.19% to create a new 52-week high of $7.34. Cyclacel Pharmaceuticals is scheduled to host a conference call today to discuss updated data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules.Cyclacel Pharmaceuticals Inc. (CYCC) announced Phase 2 results of oral sapacitabine capsules Monday morning, which showed that expected survival of elderly patients with MDS nearly doubled.Cyclacel Pharmaceuticals has been rising steadily since the open Monday and is now up 1.61 at $7.08 on above average volume. The stock has surged to a new high for the year.Cyclacel Pharmace (NGM:CYCC) is +2.2096 - +40.39% from the previous close of $5.47. It traded between $5.45 - 7.85 with total traded volume of 1157935 shares. At Current Market Price, CYCC is in the distance of +76.81% from its 50-day Moving Average price of $4.3434 and +96.89% from its 200-day Moving Average price of $3.9004.

How Should Investors React To CYCC Now? Find Out Here

Yongye International Inc (NASDAQ:YONG) escalated 17.95% to $5.65. The Board of Directors has received a preliminary, non-binding proposal letter dated October 15, 2012 from Mr. Zishen Wu. Mr. Zishen Wu is the Company’s Chairman and Chief Executive Officer, Full Alliance International Limited, MSPEA Agriculture Holding Limited and Abax Global Capital Limited to acquire all the outstanding shares of common stock of the Company not currently owned by the Buyer Parties in a going private transaction for $6.60 per share of common stock in cash.YONG received an offer to be taken private by its chief executive in a deal that values the Chinese crop nutrient developer at about $326 million. Chief Executive Zishen Wu--as part of an investor group that includes Hong Kong-based asset manager Abax Global Capital--offered to buy all the shares they don't already hold for $6.60 a share, a 38% premium over the stock's Friday closing price.

Can YONG Reach The Top? Find Out Here

Isis Pharmaceuticals (NASDAQ: ISIS) added 6.80% to $13.50 in the pre-market session. Isis Pharmaceuticals' trailing-twelve-month revenue is $123.69 million.ISIS Pharmaceuticals Inc (NASDAQ:ISIS) went up 4.83% to $13.30 on a traded volume of 818k shares.The Company said that Regulus Therapeutics Incannounced the pricing of its initial public offering of 11.25 million shares of Regulus at $4.00 per share. Isis said it purchased $3 million of Regulus common stock at the offering price and remains a significant shareholder with approximately 7 million shares.Isis Pharmaceutic (NasdaqNM:ISIS) is +0.69 - +5.46% from the previous close of $12.64. It traded between $12.97 - 14.00 with total traded volume of 2526021 shares. Keep a close eye on ISIS, as the stock has been showing unusual moves over the past weeks. At Current market price, ISIS has recovered +107.31% from its 52-week Low of 6.43 and has Pulled back -14.61% from its 52-week high of 15.61.

Can ISIS Continue To Move Higher? Find Out Here

Oppenheimer upgraded shares of New Oriental Education & Tech. Group (NYSE: EDU) from a market perform rating to an outperform rating in a report released on Monday.Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse initiated coverage on shares of New Oriental Education & Tech. Group in a research note to investors on Friday, September 28th. They set an outperform rating on the stock. Separately, analysts at Wells Fargo & Co. reiterated an outperform rating on shares of New Oriental Education & Tech. Group in a research note to investors on Friday, September 21st. Finally, analysts at Muddy Waters initiated coverage on shares of New Oriental Education & Tech. Group in a research note to investors on Wednesday, July 18th. They set a sell rating on the stock.Shares of New Oriental Education & Tech. Group opened at 17.14 on Monday. New Oriental Education & Tech. The group has a 52 week low of $9.41 and a 52 week high of $30.97. The company has a market cap of $2.656 billion and a P/E ratio of 20.16.

How Should Investors Trade EDU Now? Find Out Here

DISCLAIMER:

Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com